

Table of Contents

Contributors	xxi
About the Authors	xxiii
Foreword	xxxii
Preface	xxxiii

Volume 1

Chapter 1

The State of the Law of Claim

Construction and Infringement	1
I. Introduction	2
II. Applicants Bear the Burden to Draft Carefully	3
A. Obvious, Harmless Errors Are Correctible	3
B. Serious Errors Are Not Correctible	5
C. Avoiding Indefiniteness Requires “Reasonable Certainty” of Scope	9
III. Claim Construction	13
A. Standard of Review	13
B. <i>Phillips v. AWH</i>	15
C. General Claim Construction Principles	19
1. Applicant as Lexicographer	19
2. Disclaimer of Claim Scope	21
3. Preamble Terms and Transitional Phrases	30
4. Context of Other Claims (Claim Differentiation)	35
5. Means-Plus-Function Limitations	38
6. Other Claim Construction Principles	44
D. The PTO Applies BRI	51
IV. Infringement—Direct and Indirect	55
A. Direct Infringement: Literal Infringement	55
1. All Limitations Must Be Satisfied	60
2. Extraterritorial Acts Can Infringe	61
3. The Evidentiary Burden at Trial	63

B. Direct Infringement: Doctrine of Equivalents	65
1. Determining Equivalence: Insubstantial Difference and Triple Identity	66
2. Bars to the Doctrine of Equivalents	70
C. Indirect Infringement	82
1. Active Inducement under Section 271 (b)	83
2. Contributory Infringement under Section 271 (c)	86
3. Extraterritorial Indirect Infringement	87
V. Conclusion	90
Drafting Claims	90
Drafting the Written Description	91
Prosecution	91

Chapter 2

Pitfalls in Patent Drafting **93**

I. Introduction	95
II. Pitfalls in Drafting the Specification	99
A. Specifications Having Narrow Descriptions of “the Invention”	100
1. Titles, Field of the Invention, and Abstract	100
2. Background of the Invention, or Discussions of Prior Art	107
3. Narrow Summary of the Invention	117
4. “Objects of the Invention” and Similar Characterizations	119
B. Unintended Narrow Scope of Disclosure	122
1. Use of Language Implying Criticality	122
2. Unintentional Definitions of Claim Terms	126
3. The “Dedicated to the Public” Doctrine	134
C. Failure to Provide Sufficient Written Description/Enablement Support	139
1. Claim Overspecificity	142
2. Claim Overbreadth	143
3. Computer Software Algorithms	150
4. Referring to Prophetic Examples in the Patent	151
D. Potential Pitfalls with Provisional and Continuation-in-Part Patent Applications	152
1. Filing Provisionals for the Wrong Reasons	152
2. Dangers of “As-Is” Filings	153

3. Failure to Claim Subject Matter Supported Entirely by the Provisional or Parent (CIP) Filing	154
4. Failure to Carry Over All Subject Matter from Provisional into Nonprovisional	156
5. Failure to Establish Ownership for Provisionals	157
6. Failure to File Foreign Applications within One Year of Provisional Filing	158
III. Pitfalls in Claim Drafting	159
A. Uncertainty Regarding Whether Claim Language Is “Limiting”	160
1. Uncertainty Whether a Preamble Is Limiting	160
2. Indeterminate Scope of “Whereby” Clauses	165
3. The “Printed Matter” Doctrine	169
B. Multiparty Infringers and Divided Infringement Claims	169
1. Divided Infringement	170
2. The “Akamai” Rule	172
3. Reciting Human/User Actions in Claims	176
4. Other Issues Related to Divided Infringement	177
C. Pitfalls of Means-Plus-Function Claims	183
1. Unintended Means-Plus-Function Clauses	185
2. Attempted Means-Plus-Function Clauses Not Interpreted as Such	188
3. Single Means Claims	191
4. Failure to Clearly Link Structure in the Specification to the Recited Function	192
5. Insufficiently Described Corresponding Structure	194
D. “Functional” Claiming	198
1. Interpreting Devices with Functional Claim Language—“Capable of”	198
2. Mixed Methods and Apparatus Claims	203
E. Definiteness Problems	208
1. Use of Relative Terminology	209
2. Failure to Provide Antecedent Basis for Claim Elements	214
3. Failure to Define “Coined” Terminology	216
4. Use of Claim Terminology That Can Change over Time	217
F. Territorial Scope Problems	219
G. Failure of a Dependent Claim to Further Limit a Parent Claim	222

IV. Pitfalls in Patent Prosecution	224
A. Prosecution Disclaimer	224
B. Amendment-Based Estoppel	230
C. Argument-Based Estoppel	236
D. Family-Based Estoppel	238
E. How to “ <i>Festo</i> -Proof” a Patent Application	241
F. Clearly Link Arguments to Specific Claims	245
V. Other Problems Affecting Patent Rights or Scope	246
A. Failure to Investigate Potential Bars to Patentability	246
B. Failure to Correctly Determine Inventorship or to Establish Ownership	254
C. Failure to Claim the Commercial Embodiment	260
D. Failure to Proofread the Issued Patent	261
VI. Conclusion	262

Chapter 3

Drafting the Winning Patent **263**

I. Introduction	265
II. Patent Application Drafting—A Stepped Approach	265
A. STEP 1: Be Able to Write Clearly	266
B. STEP 2: Thoroughly Understand U.S. Patent Law and PTO Procedures and Have a Working Knowledge of Applicable International Patent Practice	269
C. STEP 3: Thoroughly Understand the Invention	270
1. The Invention Disclosure Meeting	272
2. Searching for Prior Art	284
D. STEP 4: Draft an Initial Set of Working Claims	285
1. Claim Drafting Generally	286
2. Determine What to Include in the Independent Claims	287
3. Include as Many Claim Types as Possible	289
4. Targeting Infringers in Advance: Who Will Infringe the Claim?	292
5. Selecting Dependent Claim Features	293
E. STEP 5: Prepare Working Drawing Figures (If the Application Will Include Drawings)	294
F. STEP 6: Draft the Detailed Description Portion of the Specification	297
1. Things to Remember	297
2. Thoughtfully and Logically Organize the Specification	298

3. Avoid Unnecessary Repetition	299
4. Do Not Assume That the Reader Is Starting from the Same Knowledge Base	300
5. Strive for Clarity and Readability, but Remember Claim Construction during Litigation	300
6. Include Multiple Embodiments and Examples	303
7. Include Self-Serving Statements and Boilerplate, but Do Not Rely on Them	305
8. Include Broad Definitions of Claim Terms	307
9. Use Terminology Consistently in the Specification and Claims	310
10. Favor Over-Inclusion Rather Than Under-Inclusion	311
11. Use Incorporation by Reference Carefully	313
12. Provide Support for Any Means-Plus-Function Claims	316
G. STEP 7: Draft the Summary Portion of the Specification	317
H. STEP 8: Draft the Background Portion of the Specification	318
I. STEP 9: Revise the Claims	320
1. Recite a Minimum Number of Elements in Independent Claims	320
2. Include Claims of Broad, Intermediate, and Narrow Scope	322
3. How Many Claims Are Appropriate?	324
4. Use a Variety of Claim Terminology Consistent with the Specification	325
5. Rely on Claim Differentiation to Maximize Claim Scope	326
6. Carefully Select Preamble and Transition Phrases	327
7. Try to Design around Your Own Claims	329
8. Using Terms of Approximation	330
9. Carefully Consider Linkages among Elements	331
10. Avoiding Indemnity Agreements among Vendors	333
11. Maximizing Damages and Royalties through Claim Drafting	336
J. STEP 10: Proofread the Specification, Claims, and Drawings	339
K. STEP 11: Revise the Application Based on Inventor Review and Then Proofread It Again	340
III. Checklists for Drafting and Prosecution	340
A. Pre-Drafting Checklist	340
B. Pre-Filing Checklist	341
C. Checklist for Official Filing Receipt and Recorded Assignment	345

D. Checklist for First Office Action	346
E. Checklist for Patent Prosecution	346
F. Checklist for Notice of Allowance	347
G. Checklist for Granted Patent	347
IV. Conclusion	348

Chapter 4

Continued Prosecution of the Patent 349

I. Introduction	350
II. The Family of Continuing Applications	352
A. Continuations	352
1. Earlier Application Must Satisfy 35 U.S.C. § 112(a)	354
2. Requirement for At Least One Common Inventor	355
3. Coadependency Requirement	356
4. Specific Reference Requirement	359
5. Continuity of Disclosure	361
B. CIPs	362
C. Divisionals	366
D. Continuing Prosecution Strategy	374
III. Prosecution Laches	377
IV. Certificates of Correction	383
V. Reissues	386
A. The Patent for the Invention	388
B. Through Error, Patent Deemed Wholly or Partly Inoperative or Invalid	390
1. Errors Generally	390
2. Recapture	393
C. Broadening Reissue	399
D. Intervening Rights	401
E. Reissue Strategy	403
VI. Reexaminations	404
A. Ex Parte Reexamination	406
1. The Request	406
2. Institution of Ex Parte Reexamination	408
3. Patent Owner Response	410
4. Prosecution of Ex Parte Reexamination	411
5. Appeal and Certificate	415
B. Inter Partes Reexamination	416
C. Intervening Rights	419

D. Reexamination Strategy	421
1. Cost	422
2. Strengthening the Patent	422
3. Adding More Claims	423
4. Patent Owner Requests	423
5. Stays of Litigation	424
VII. Supplemental Examination	425
A. Scope of and Procedures for Supplemental Examination	426
B. Modified Ex Parte Reexamination Procedures Following Supplemental Examination	429
C. PTO Discovery of Fraud	431
D. Supplemental Examination's Impact on Litigation and Enforcement Strategies	432
VIII. Conclusion	434

Chapter 5

Mechanical Patents **435**

I. Introduction	436
II. Validity of Mechanical Patents	439
A. Written Description Issues	440
1. The Traditional Rule: Mechanical Technologies Are Predictable	441
2. Predictability in the Mechanical Arts after <i>Gentry Gallery</i>	443
3. Do Not Rely on Predictability for Mechanical Technologies	446
B. Enablement Issues	450
C. Definiteness Issues	453
1. The Pre- <i>Nautilus</i> Standard for Indefiniteness—"Insolubly Ambiguous"	454
2. The <i>Nautilus</i> Standard for Indefiniteness—"Reasonable Certainty"	456
3. Terms of Degree and Other Potential Indefiniteness Problems in Mechanical Patents	461
D. Obviousness Issues	476
III. Claim Scope and Interpretation of Mechanical Patents	482
A. Ordinary Meaning	483
B. Avoiding Narrow Claim Scope	489
1. The Critical Importance of the Written Description	493
2. Maximizing Claim Scope in Mechanical Patents	496

C. Means-Plus-Function Limitations in Mechanical Patents	545
1. Careful Use of Means-Plus-Function Claiming in Mechanical Cases	546
2. Avoid Recitation of Structure	549
3. Disclose Multiple Embodiments of Corresponding Structure	552
4. Always Clearly Link Corresponding Structure to the Claimed Functions	558
5. Avoid Unintentional Invocation of Section 112(f)	560
6. The Mysterious and Elusive Step-Plus-Function Claim	566
IV. Other Enforcement Issues	567
A. Some Sage Advice from the Federal Circuit Regarding Claim Drafting	568
B. In Mechanical Cases, It May Be Difficult to Rebut the <i>Festo</i> Presumption	575
V. Conclusion	579

Chapter 6

Electrical Patents **581**

I. Introduction	582
II. Claim Considerations	582
A. Planning the Claim Strategy	582
B. Subject Matter Eligibility	586
C. Multiple Actors and Divided Infringement	590
D. Means-Plus-Function	592
E. Technical Accuracy	600
F. Scope of the Specification	602
G. Definiteness Problems	611
H. Mixing Statutory Classes	615
I. Grammar	616
J. “Real-Time”	619
K. “Predetermined”	621
L. “At Least One of A, B, and C” . . . or . . .	621
M. Absolute Terms	624
N. Semiconductor Devices	625
III. Written Description Considerations	626
A. Basic Legal Requirements	626
B. The Importance of Advantages	627
C. Support for Electrical Structures	629

D. Systems Including Paired Operations	641
E. Care with Limiting Statements	648
F. Steps Performed outside the United States	661
G. The “Invention”	663
IV. Drawing Considerations	668
V. Conclusion	670

Volume 2

Chapter 7

Software, E-Commerce, Internet, and Business Method

Patents 671

I. Introduction	672
II. Validity of Software-Related Patents	673
A. Written Description Issues	673
B. Enablement Issues	678
C. Best Mode Issues	681
D. Definiteness Issues	682
1. Means- or Step-Plus-Function Recitations	687
E. Patent-Eligible Subject Matter Issues	695
1. Supreme Court Precedent	696
2. Current Test to Determine Statutory Subject Matter	709
3. Previous Tests to Determine Statutory Subject Matter	731
III. Claim Scope and Interpretation of Software-Related Patents	734
A. Claims for Software-Related Inventions	734
1. Process Claims	735
2. Apparatus Claims	739
3. System Claims	741
4. Claims with Means- or Step-Plus-Function Recitations	743
5. Data Structure Claims	747
6. Computer-Readable Medium Claims	749
7. Non-Viable Claim Formats	751
B. Business Method Inventions	756
1. Software-Related Business Method Inventions	756
2. Non-Software-Related Business Method Inventions	759
3. Post-Grant Review of Business Method Patents	762
4. Summary	765

C. Claiming Strategies	765
1. Claiming a Network or Internet Invention	766
2. Claiming a Network Router Invention	769
3. Claiming an E-Commerce Website Invention	769
4. Claiming a Simulation Software Invention	771
IV. Conclusion	773

Chapter 8

Chemical and Pharmaceutical Patents **775**

I. Introduction	776
II. Validity of Chemical and Pharmaceutical Patents	777
A. Written Description Issues	777
B. Enablement Issues	785
C. Best Mode Issues	789
D. Utility Issues	792
E. Patentable Subject Matter	796
F. Anticipation Issues in Chemical Applications: Inherency	799
1. Inherent Anticipation Is Not Avoided by Discovery of a New Benefit or Property of an Old Material or Method	799
2. Metabolite Claims Can Be Anticipated If the Metabolite Was Formed In Vivo after Administration of the Prior Art Drug	801
3. Creative Claim Drafting Can Often Overcome Inherent Anticipation Problems	803
4. A Sufficiently Small Prior Art Genus Can Anticipate a Later-Claimed Species	805
G. Obviousness Issues in Chemical and Pharmaceutical Patents	809
1. Pre-KSR Standards for Chemical Obviousness	811
2. Post-KSR Chemical Obviousness	812
H. Double Patenting Issues in Chemical Cases	818
III. Claim Scope and Interpretation of Chemical and Pharmaceutical Patents	822
A. Claim Scope Issues in Chemical and Pharmaceutical Patents	822
1. Markush Groups	822
2. Transitional Phrases in Chemical Claims	830
3. Product-by-Process Claims	835
B. Means-Plus-Function Limitations	838
C. Claim Drafting Strategies	839
1. Careful Consideration of the Life Cycle of the Chemical Product Should Be Undertaken to Ensure the Appropriate Aspects of the Invention Are Included	839

2. Pharmaceutical Claims to Methods of Treatment	849
3. Pharmaceutical Claims to Homologs, Stereoisomers, Racemates, Salt Forms, and Metabolites	852
D. Claim Interpretation	853
1. Implicit and Explicit Definitions of Claim Terminology	853
2. The Effect of Examples and Preferred Embodiments on Claim Construction	862
3. Interrelationship of Claims	867
4. Prosecution History: Disclaimers and Estoppel	868
5. Use of Extrinsic Evidence in Interpreting Chemical Claims	872
IV. Conclusion	876

Chapter 9

Biotechnology Patents **877**

I. Introduction	879
II. Validity Issues Related to Biotechnology Patents	879
A. Considerations under 35 U.S.C. § 101	879
1. Patent-Eligible Subject Matter	879
2. Utility	894
B. Considerations under 35 U.S.C. § 112	895
1. Enablement as of the Date of Filing and After-Arising Technology	896
2. Written Description and Biological Organisms Deposited with the ATCC	898
3. Written Description and DNA-Based Inventions	899
4. Written Description of Antibodies	901
5. Enablement and Written Description and Post-Priority Date Evidence	904
6. Indefiniteness	905
C. Challenging Patent Validity under the AIA	906
III. Claim Scope and Interpretation of Biotechnology Patents	909
A. Claim Scope Is Fixed as of the Filing Date	910
B. Process Limitations and Product Claims	913
C. Interpreting Claims in Light of the Specification	915
1. Multiple Interpretations of a Claim versus a Single, Unambiguous Meaning	916
2. Expansive Interpretation of a Claim Term May Result from the Use of Varied Terms, or the Use of the Term in Different Contexts, in the Specification	917

3. Avoiding Restriction of the Invention to the Disclosed Preferred Embodiment	919
4. Relative Terms: “Substantially,” “About,” and “At Least”	924
5. Calculations	925
D. The Role of the Preamble in Biotechnology Claims	926
1. <i>Griffin v. Bertina</i>	927
2. <i>Manning v. Paradis</i>	927
3. <i>Rapoport v. Dement</i> and <i>Jansen v. Rexall Sundown, Inc.</i>	929
4. <i>In re Cruciferous Sprout Litigation</i>	930
5. <i>Boehringer Ingelheim Vetmedica, Inc. v. Schering-Plough Corp.</i>	931
E. Nontraditional Claim Language	931
IV. Infringement Considerations	932
A. 35 U.S.C. § 271(f)(1) and the Supply of a Single Component	932
B. Joint or Divided Infringement of Process Claims	933
V. Other Enforcement and Prosecution Issues	935
A. The Doctrine of Equivalents Applied to Proteins and Nucleic Acid Molecules	935
B. Challenges Based on Obviousness	938
C. Miscellaneous Points for Biotechnology Patents	941
1. Arguments of a Licensee or Potential Licensee	941
2. Distribution and Licensing Agreement and the On-Sale Bar under the AIA	942
3. Statements Made to Governmental Agencies	943
4. Inequitable Conduct	943
5. Patent Exhaustion	944
VI. Considerations and Overlap with Regulatory Requirements	946
A. The Orange Book and the Timing of Drug Approvals	946
1. The Requirements for Listing of Patents in the Orange Book	947
2. Patents That Must Not Be Submitted	951
B. Patents That May Be Granted Patent Term Extension for Delays Due to Regulatory Delays	952
1. Length of Extension	955
2. Scope of Extension	956
C. Follow-On Biologics	957
1. Biologics Price Competition and Innovations Act Litigation Pathway	957
2. <i>Sandoz v. Amgen</i> and the Patent Dance	959
3. Blind Filings and Future Guidance	962
VII. Conclusion	964

Chapter 10	
Design Patents	965
I. Introduction and Design Law Principles	966
A. Licensing and Enforcement	967
B. Application of Utility Laws and Evolution	968
C. Infringement of Design Patents	969
1. Introduction	969
2. Claim Construction	970
3. Prior Infringement Test— <i>Pre-Egyptian Goddess</i>	973
4. Current Infringement Test— <i>Post-Egyptian Goddess</i>	976
II. Practice Essentials	980
A. Understanding and Applying the Essential Concepts	980
1. Introduction	980
2. Portion Practice	980
3. Design Claims Are Not Broad or Narrow	981
4. Consideration of Multiple Applications Should Be the Rule	985
5. Design Patents Do Not Protect Concepts	986
B. Sculpting the Design Claim	988
1. Responsibility and Technique	988
2. Aesthetic Significance of Features	989
3. Functionality of Features	998
4. Prior Art Considerations	1006
C. Creatively Presenting the Design Claim	1008
D. Accurately Presenting the Design Claim	1010
E. Avoid Multiple Embodiments in a Single Design Patent	1015
F. Expanding Options with Strategic Continuation Practice	1022
1. Introduction	1022
2. Utility-Design Priority	1022
3. Design-Utility Priority	1023
4. Design-Design Priority	1024
G. Special Considerations—Branding Efforts and Nontraditional Articles	1028
1. Protect More Than Just the Core Product	1028
2. Product Packaging	1029
3. Promotional and Peripheral Products	1029
4. Computer Icons and Graphical User Interfaces	1030
5. Type Fonts	1032
6. Physical Settings	1034

H. Controlling the Timing	1034
1. General	1034
2. Speeding Up	1034
3. Slowing Down	1036
I. Think Globally: How International Practice Affects U.S. Practice	1038
III. Conclusion	1039

Chapter 11

Combining Prosecution with Other Forms of Representation

1041

I. Introduction	1042
II. Identifying Potentially Applicable Standards of Discipline, Ethics, and Care	1042
A. The Two Different Standards Applied by the PTO to Ethical Issues during Prosecution	1045
1. OED Discipline	1046
2. PTO Disqualification	1049
3. Preemption of State Rules by the USPTO Rules	1051
B. Federal Circuit Choice of Law	1054
C. Conclusion on Choice of Law	1056
III. Combining Litigation with Prosecuting Patent Applications, Acquiring Patents, and Other Forms of Representation	1057
A. The Risk of Inadvertent Misuse of Information Disclosed in Discovery to a Litigator Who Performs Other Functions for a Client	1057
1. The General Framework to Determine Whether Litigators Who Also Prosecute Patent Applications Should Be Barred from Access to an Opposing Party's Highly Confidential Information	1059
2. Barring a Litigator Who Also Represents Clients in Post-Grant Proceedings at the PTO, Advises on Patent Acquisition, or Engages in Other Forms of Representation	1068
3. Issues Counsel Should Consider in Negotiating Bars in Protective Orders	1073
B. Liability and Disqualification of Prosecuting-Litigators	1085
1. Inequitable Conduct as a Conflict	1085
2. Depositions of Prosecuting-Litigators	1087
C. Advocate-as-Witness Disqualification	1090

IV. Combining Opinion and Trial Representations	1093
A. Advocate-as-Witness Disqualification	1094
1. The Courts Split on Advocate-as-Witness Disqualification	1095
2. What to Do	1098
B. Enhanced Risk of Waiver of Work Product	1098
C. What to Do	1108
V. Conclusion	1109

Chapter 12

Drafting U.S. Patents with a View toward Europe **1111**

I. Introduction	1113
A. Brief History of the Development of the EPO	1113
B. Applicable Law	1116
II. Requirements for the Description of an EPO Application	1117
A. Sufficiency of Disclosure—Article 83 EPC	1117
B. Content of the Application—Rule 42 EPC	1117
C. Summary	1120
III. The Claims	1120
A. Overview	1120
B. Content of the Claims—Article 84 EPC	1122
C. Rule 43(1) EPC—Two-Part “Characterized” Form Preferred	1122
1. Two-Part Form Not Needed for Filing	1123
2. Two-Part Form Only “Whenever Appropriate”	1124
D. Only One Independent Claim of Each Category Permitted Except in Special, Limited Circumstances	1125
1. Plurality of Interrelated Products—Rule 43(2) (a) EPC	1126
2. Different Uses of a Product or Apparatus—Rule 43(2)(b) EPC	1126
3. Alternative Solutions to a Particular Problem—Rule 43(2)(c) EPC	1126
E. Dependent Claims Permitted	1126
F. There Can Be Multiple Dependent Claims	1127
G. No Limit on the Number of Claims	1128
H. The Claims Should Preferably Include Reference Numerals	1128
IV. Unity of Invention	1129
A. Lack of Unity “a Priori” and “a Posteriori”	1130
B. Claims of Different Categories	1131
C. Divisional Applications	1131

V.	Other Issues concerning the Claims	1131
A.	Alternatives and Markush Groupings	1132
B.	Jepson Claims	1132
C.	“Means for” Language	1132
D.	Computer-Implemented Inventions and Business Methods	1132
E.	Beauregard Claims	1134
F.	Product-by-Process Claims	1134
G.	Method of Treatment Claims	1135
1.	First Medical Use Claims—Article 54(4) EPC	1136
2.	Second Medical Use Claims—Article 54(5) EPC	1137
3.	Practical Advice on Claim Drafting for Methods of Treatment	1137
H.	Stem Cells	1138
I.	The EP Approach to Added Matter—Claim Drafting Ramifications	1139
J.	Continuation and Divisional Applications	1142
1.	Continuation Applications	1142
2.	CIP Applications	1143
K.	Plausibility	1144
L.	Parameters	1145
VI.	Practical Guidance	1146
VII.	When to Revise the Specification	1148
A.	Paris Convention Route	1148
B.	Ex-PCT Route	1148
VIII.	Post-Grant Issues	1149
A.	The Extent of Protection	1149
1.	Harmonization of Different Traditional National Approaches	1149
2.	Equivalents	1150
B.	Unitary Patents and the UPC	1154
C.	File Wrapper Estoppel	1159
D.	Forum Shopping	1160

Chapter 13

Validity Trials at the Patent Trial and Appeal Board 1165

I.	Introduction to Post-Issuance Trial Proceedings	1167
II.	Trial Procedures before the PTAB	1169
A.	Scheduling	1170

B. Motions Practice	1172
1. Motions to Amend	1173
2. Motions to Exclude and Motions to Strike	1178
C. Discovery	1180
1. Initial Disclosures	1180
2. Testimonial Discovery	1181
3. Documentary Discovery	1183
D. Treatment of Confidential Information	1186
E. Use of the Federal Rules of Evidence and Handling of Exhibits	1188
F. Oral Argument	1189
G. Final Written Decision and Its Impact on Patentees	1191
H. Settlement	1195
I. Regulation of Conduct of Counsel and Parties and Sanctions	1196
III. IPR	1200
A. Constitutional Challenges	1201
B. Standing and Other Limitations	1202
1. Unavailability of IPR While PGR Is Available	1203
2. One-Year Bar	1203
3. Declaratory Judgment of Invalidity	1211
4. Claim and Issue Preclusion	1211
5. Discretion to Institute under Section 314(a): Parallel Proceedings	1212
6. Discretion to Institute under Section 325(d): Prior Art or Arguments Already Considered by the PTO	1213
7. Discretion to Institute under Section 314(a) and Section 325(d): Multiple Petitions	1216
8. Assignor Estoppel	1219
9. Sovereign Immunity	1220
C. Preliminary Proceedings	1221
1. Overview	1221
2. Claim Construction	1225
D. Trial Proceedings	1225
1. Threshold Standard for Institution	1225
2. Timing and Content of Institution Decision	1226
3. Scope of Review and SAS Institute	1226
4. Patent Owner's Discovery Period and Response	1228
5. Oral Hearing	1228

6. Final Written Decision	1228
7. Joinder and Concurrent Proceedings	1229
E. Appeal	1230
1. Procedures	1230
2. Limits on Appellate Jurisdiction	1230
3. Appealability of the Institution Decision	1233
F. Impact on Litigation and Patent Procurement Strategies	1234
IV. PGR	1237
A. Scope of PGR	1237
B. Preliminary Proceedings	1240
C. Trial Proceedings	1240
D. Appeal	1242
E. Impact on Litigation Strategies	1242
V. Transitional Program for CBM Patents	1244
A. Overview	1245
B. Sunset	1248
VI. Conclusion	1249
Table of Cases	1251
Index	1325